Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Cancer Discovery|June 3, 2023
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation StudyPatricia LoRusso, Noboru Yamamoto, Manish R Patel, et al.
Investigational New Drugs|May 11, 2002
Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing miceLisa Polin, Kathryn White, Juiwanna Kushner, et al.
Investigational New Drugs|September 22, 2016
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumorsAlex A Adjei, Patricia LoRusso, Antoni Ribas, et al.
Investigational New Drugs|January 24, 2004
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignanciesJoseph P Eder, Rocio Garcia-Carbonero, Jeffrey W Clark, et al.
The Oncologist|August 2, 2023
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid TumorsElena Garralda, Alison M Schram, Philippe L Bedard, et al.
Future Oncology (London, England)|January 16, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumorsKevin Harrington, Shigehisa Kitano, Valentina Gambardella, et al.
Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.
The Oncologist|June 10, 2015
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody CixutumumabNaifa L Busaidy, Patricia LoRusso, Kristie Lawhorn, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 studyAnthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Pageof 17